Standard-essential patents (SEPs) are among the most valuable assets in today’s technology economy. They form the foundation of licensing programs, determine competitive positioning, and increasingly become the center of high-stakes litigation across multiple jurisdictions. Yet one reality remains unchanged: many SEPs that initially appear to be strong eventually fail when scrutinized in court.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision Tuesday in Cocona, Inc. v. VF Outdoor, LLC, affirming a judgment of the U.S. District Court for the District of Colorado that held three claims of a waterproof, breathable membrane patent invalid as indefinite. Circuit Judge Stark wrote for the court, joined by Circuit Judges Lourie and Stoll, and agreed with the district court that the asserted claims recited a numerical range for moisture vapor transmission rate (MVTR) without specifying a method for measuring it.
The full Senate Judiciary Committee today heard from five witnesses who urged senators to take action to curb pharmaceutical industry and pharmacy benefit manager (PBM) practices, which they alternately blamed for high U.S. drug costs. While some senators warned that targeting drug makers could have unintended consequences, most supported moving quickly on legislation they claim would lower prices for U.S. consumers, a claim industry has called a “myth”.
Critics of the pharmaceutical patent system often claim that manufacturers use large patent portfolios to delay competition. A new paper in the Journal of Law and the Biosciences offers the latest version of that argument, focusing specifically on biologics. The authors compare biologic patent portfolios in the United States, Europe, and Japan. They find that the largest patent portfolios are in the United States—and that biologics are associated with more patents than traditional small-molecule drugs. This may be true, but it does not demonstrate that a problem exists.
This week on IPWatchdog Unleashed, we discuss how a credible trial preparation supports settlement leverage. From the in-house vantage point, a litigation team’s ability to articulate a persuasive case matters even when the preferred outcome is an early resolution. For patent owners, accused infringers, and the counsel advising them, this conversation highlights why audience awareness, technical clarity, and case development belong within the same strategy. The episode offers a substantive look at how experienced practitioners make those judgments—and how the choices made throughout a case shape both courtroom advocacy and the options available outside it.
Uncertainty in patent rights undermines the investment needed to turn scientific breakthroughs into commercial products—but accepting that uncertainty is a choice. In this episode of IPWatchdog Unleashed, Judge Pauline Newman draws on her experience in industry and the policy discussions that helped shape the Federal Circuit to connect today’s life sciences challenges with the conditions that drove an earlier era of patent reform. She explains why predictable, reliable patent protection matters to research investment, commercialization, and the ability to recover the costs of failed research as well as successful discoveries. Her message to IP counsel, industry leaders, and policymakers is direct: addressing the weaknesses of the patent system requires looking beyond how to navigate existing law and engaging in the work of changing it.
This week on IPWatchdog Unleashed, we have a discussion about the IP risks associated with AI use and adoption, with Stephanie Curcio, Marlene Valderrama, Kendra Ervin and Rinat Shangeeta. The discussion reveals a consequential gap with how businesses are deploying AI. Many companies are moving faster to adopt AI than their governance, contracting and IP review processes can accommodate. For those responsible for protecting innovation and confidential information, the challenge is ensuring that enthusiasm for AI adoption does not obscure the consequences of how these tools are actually used.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision on Monday in Traxcell Technologies, LLC v. Cellco Partnership, dba Verizon Wireless, vacating a judgment of the U.S. District Court for the Western District of Texas and remanding with instructions to dismiss Traxcell’s independent action for lack of jurisdiction. Traxcell brought the action seeking to void an attorneys’ fee award that the U.S. District Court for the Eastern District of Texas granted to Verizon under 35 U.S.C. Section 285, an award the CAFC had previously affirmed.
Last Friday, U.S. District Judge Natasha Merle of the Eastern District of New York entered an order adopting a U.S. magistrate judge’s report and recommendation to grant Gilead Sciences’ motion for default judgment against eight individuals and 18 shell companies involved in a conspiracy to market counterfeit HIV treatments, many of them improperly labelled and sold with falsified chain-of-sale documents.
Imports of Chinese electric and hybrid vehicles are transforming Brazil’s automotive market. At the same time, data from the Brazilian Patent and Trademark Office (BPTO) show Chinese companies expanding their patent presence. Together, these trends suggest a new phase of competition in which electrification, software and artificial intelligence (AI) may matter as much as manufacturing scale and dealer networks.
The USPTO deserves some credit for recognizing that applicants may at times need an opportunity to explain technical improvements that examiners have failed to appreciate, but there is real risk associated with filing a SMED that should cause practitioners to pause rather than race forward without serious consideration. And despite some difference of opinion, we all agreed on an essential point: Filing a SMED should not be the first line of defense against an eligibility rejection; it should should be treated as a last resort. Filing a SMED requires serious consideration of the advantages, disadvantages, and alternatives. Examiner interviews, arguments grounded in the existing specification, appropriate claim amendments, and appeals all deserve careful consideration before ever adding sworn statements to the prosecution history. The question must be whether the declaration supplies something genuinely necessary to advance the case, and even then must be intentionally specific and narrow.
A patent’s economic value and the price it commands in a licensing negotiation can be very different things. The technology may deliver substantial commercial benefits, yet the amount a patent owner can capture depends on legal risk, enforcement costs, negotiating leverage, and each party’s business objectives. This week on IPWatchdog Unleashed, we ask how much a patent is really worth, and how to prove it at a negotiating table or in court. This conversation, which occurred as part of IPWatchdog’s 2026 Women’s IP Forum, examines how sophisticated licensors, licensees, counsel, and valuation professionals assess patent value in real-world transactions and disputes. The conversation explored royalty structures, comparable licenses, portfolio strength, litigation and validity risk, damages principles, standard-essential patent (SEP) licensing, and the practical factors that drive parties toward—or away from—a deal.
This week on IPWatchdog Unleashed, I speak with Nancy Braman. Recorded before a live audience at IPWatchdog’s 2026 Women’s IP Forum, our conversation explores how practitioners create opportunities, develop professional relationships, and build the skills necessary to succeed in patent law. From taking PLI patent bar review course before law school, to attending Franklin Pierce Law School, to spending more than three years writing and researching for IPWatchdog and now litigating high-stakes patent and intellectual property disputes for life sciences and technology companies. She has already had quite the journey, and I sense it is really just beginning.
This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.
Get Email Updates